Frederic Pouzoulet

Frederic Pouzoulet

Auto-generated profile, based on publicly available information

Frederic Pouzoulet

Institut Curie, PSL Research University, Translational Research Department, Experimental Radiotherapy Platform, Orsay, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2014 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
VFVincent Favaudon
Vincent Favaudon
LCLaura Caplier
Laura Caplier
virginie monceauvirginie monceau
virginie monceau
FPFrédéric Pouzoulet
Frédéric Pouzoulet
MSMano Sayarath
Mano Sayarath
MVMarie-Catherine Vozenin
Marie-Catherine Vozenin
In vitro studies suggested that sub-millisecond pulses of radiation elicit less genomic instability than continuous, protracted irradiation at the same total dose. To determine the potential of ultrahigh dose-rate irradiation in radiotherapy, we investigated lung fibrogenesis in C57BL/6J mice exposed either to short pulses (≤500 ms) of radiation delivered at ultrahigh dose rate (≥40 Gy/s, FLASH) or to conventional dose-rate irradiation (≤0.03 Gy/s, CONV) in single doses. The growth of human HBCx-12A and HEp-2 tumor xenografts in nude mice and syngeneic TC-1 Luc+ orthotopic lung tumors in C57BL/6J mice was monitored under similar radiation conditions. CONV (15 Gy) triggered lung fibrosis associated with activation of the TGF-β (transforming growth factor–β) cascade, whereas no complications developed after doses of FLASH below 20 Gy for more than 36 weeks after irradiation. FLASH irradiation also spared normal smooth muscle and epithelial cells from acute radiation-induced apoptosis, which could be reinduced by administration of systemic TNF-α (tumor necrosis factor–α) before irradiation. In contrast, FLASH was as efficient as CONV in the repression of tumor growth. Together, these results suggest that FLASH radiotherapy might allow complete eradication of lung tumors and reduce the occurrence and severity of early and late complications affecting normal tissue.

1 April 2009 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
TET.G. Ebrahimian
T.G. Ebrahimian
FPF. Pouzoulet
F. Pouzoulet
CSC. Squiban
C. Squiban
VBV. Buard
V. Buard
MAM. André
M. André
RTR. Tamarat
R. Tamarat
Objective— We hypothesized that adipose tissue may contain progenitors cells with cutaneous and angiogenic potential. Methods and Results— Adipose tissue-derived stroma cells (ADSCs) were administrated to skin punched wounds of both nonirradiated and irradiated mice (20 Gy, locally). At day14, ADSCs promoted dermal wound healing and enhanced wound closure, viscolesticity, and collagen tissue secretion in both irradiated and nonirradiated mice. Interestingly, GFP-positive ADSCs incorporated in dermal and epidermal tissue in vivo and expressed epidermal markers K5 and K14. Cultured ADSCs in keratinocyte medium have been shown to differentiate into K5- and K14-positive cells and produced high levels of KGF. At Day 7, ADSCs also improved skin blood perfusion assessed by laser Doppler imaging, capillary density, and VEGF plasma levels in both irradiated and nonirradiated animals. GFP-positive ADSCs incorporated into capillary structures in vivo and expressed the endothelial cell marker CD31. Finally, in situ interphase fluorescence hybridization showed that a small number of ADSCs have the potential to fuse with endogenous keratinocytes. Conclusion— ADSCs participate in dermal wound healing in physiological and pathological conditions by their ability to promote reepithelialization and angiogenesis. Hence, adipose lineage cells represent a new cell source for therapeutic dermal wound healing.

1 November 2018 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
APAnnalisa Patriarca
Annalisa Patriarca
CFCharles Fouillade
Charles Fouillade
MAMichel Auger
Michel Auger
FMFrédéric Martin
Frédéric Martin
FPFrédéric Pouzoulet
Frédéric Pouzoulet
LMLudovic De Marzi
Ludovic De Marzi

31 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
yolanda prezadoyolanda prezado
yolanda prezado
GJGregory Jouvion
Gregory Jouvion
DHDavid Hardy
David Hardy
APAnnalisa Patriarca
Annalisa Patriarca
CNCatherine Nauraye
Catherine Nauraye
FPFrederic Pouzoulet
Frederic Pouzoulet
Proton minibeam radiation therapy (pMBRT) is a novel strategy for minimizing normal tissue damage resulting from radiotherapy treatments. This strategy partners the inherent advantages of protons for radiotherapy with the gain in normal tissue preservation observed upon irradiation with narrow, spatially fractionated beams. In this study, whole brains (excluding the olfactory bulb) of Fischer 344 rats (n = 16) were irradiated at the Orsay Proton Therapy Center. Half of the animals received standard proton irradiation, while the other half were irradiated with pMBRT at the same average dose (25 Gy in one fraction). The animals were followed-up for 6 months. A magnetic resonance imaging (MRI) study using a 7-T small-animal MRI scanner was performed along with a histological analysis. Rats treated with conventional proton irradiation exhibited severe moist desquamation, permanent epilation and substantial brain damage. In contrast, rats in the pMBRT group exhibited no skin damage, reversible epilation and significantly reduced brain damage; some brain damage was observed in only one out of the eight irradiated rats. These results demonstrate that pMBRT leads to an increase in normal tissue resistance. This net gain in normal tissue sparing can lead to the efficient treatment of very radio-resistant tumours, which are currently mostly treated palliatively.

1 June 2019 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
yolanda prezadoyolanda prezado
yolanda prezado
GJGregory Jouvion
Gregory Jouvion
CGConsuelo Guardiola
Consuelo Guardiola
WGWilfredo Gonzalez
Wilfredo Gonzalez
MJMarjorie Juchaux
Marjorie Juchaux
RDRemi Dendale
Remi Dendale

7 November 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
yolanda prezadoyolanda prezado
yolanda prezado
GJGregory Jouvion
Gregory Jouvion
APAnnalisa Patriarca
Annalisa Patriarca
CNCatherine Nauraye
Catherine Nauraye
CGConsuelo Guardiola
Consuelo Guardiola
FPFrederic Pouzoulet
Frederic Pouzoulet
Proton minibeam radiation therapy (pMBRT) is a novel strategy which has already shown a remarkable reduction in neurotoxicity as to compared with standard proton therapy. Here we report on the first evaluation of tumor control effectiveness in glioma bearing rats with highly spatially modulated proton beams. Whole brains (excluding the olfactory bulb) of Fischer 344 rats were irradiated. Four groups of animals were considered: a control group (RG2 tumor bearing rats), a second group of RG2 tumor-bearing rats and a third group of normal rats that received pMBRT (70 Gy peak dose in one fraction) with very heterogeneous dose distributions, and a control group of normal rats. The tumor-bearing and normal animals were followed-up for 6 months and one year, respectively. pMBRT leads to a significant tumor control and tumor eradication in 22% of the cases. No substantial brain damage which confirms the widening of the therapeutic window for high-grade gliomas offered by pMBRT. Additionally, the fact that large areas of the brain can be irradiated with pMBRT without significant side effects, would allow facing the infiltrative nature of gliomas.